Monograph Details
|
|
Eye Disorders
> Glaucoma
|
|
XALATAN |
| Manufacturer |
|
Pfizer Ophthalmics |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Prostanoid. |
| Generic Name |
|
Latanoprost 0.005%; oph soln; contains benzalkonium chloride. |
| Indications |
|
Open-angle glaucoma. Ocular hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
1 drop once daily in the PM. |
| Precautions |
|
Do not exceed recommended dose (may reduce efficacy). Ocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Allow at least 5 minutes between application of other topical oph agents. |
| Adverse Reactions |
|
Blurred vision, burning, stinging, conjunctival hyperemia, foreign body sensation, itching, other local reactions, increased ocular pigmentation (eg, iris, eyelid, eyelashes; may be permanent), other eyelash changes, punctate epithelial keratopathy, photophobia, upper respiratory tract infection, pain, angina, rash, macular edema. |
| How Supplied |
|
Soln—2.5mL |
|
|
|
|
